Queen's Birthday Honour for Professor Richard Scolyer

 Queen's Birthday Honour for Professor Richard Scolyer

13 June 2021

Melanoma Institute Australia Co-Medical Director and Professor at The University of Sydney, Professor Richard Scolyer, has been recognised in the 2021 Queen’s Birthday Honours List announced today by the Governor-General.

Professor Scolyer has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly in the field of melanoma and skin cancer, as a clinician, researcher and educator, and to national and international professional organisations.

Professor Scolyer, born and raised in Launceston, is the world’s most published scientist in the field of melanoma pathology. For two decades he has been at the forefront of virtually all major advances in melanoma, resulting in vast improvements in survival of melanoma patients.

‘Professor Scolyer’s pioneering research, underpinned by his talent, passion and determination, has changed the face of melanoma diagnosis, treatment and survival, and saved many thousands of lives from melanoma,’ said fellow MIA Co-Medical Director, Professor Georgina Long AO.

‘Less than a decade ago, advanced melanoma was an almost certain death sentence, but thanks in no small part to Professor Scolyer’s ground-breaking research and diagnostic breakthroughs we are now steadfast on a course towards reaching zero deaths from this insidious disease.’

Each year, Professor Scolyer receives more than 2,000 of the most difficult cases from around the world for review and diagnosis.

He co-leads MIA, the world’s largest melanoma research and treatment facility, as well as the world-renowned translational research laboratory at The University of Sydney with his colleague and long-time friend Professor Long AO. He is also a senior specialist at Royal Prince Alfred Hospital & NSW Health Pathology.

‘It is a proud day for all of us at Melanoma Institute Australia who see first-hand Professor Scolyer’s life-saving contribution to cancer diagnosis and treatment,’ said MIA CEO Matthew Browne. ‘His inclusion in today’s Queen’s Birthday Honours List could not be more well deserved,’ he added.

Professor Scolyer has co-authored more than 700 peer reviewed publications/book-chapters including in prestigious journals such as New England Journal of Medicine, Lancet, Nature, Cell, Nature Genetics, Lancet Oncology, Journal of Clinical Oncology, Journal of the National Cancer Institute and Cancer Discovery and has presented on more than 370 occasions at conferences throughout the world.

Professor Scolyer’s Queen’s Birthday Honour follows numerous awards including being named the 2020 Outstanding Researcher of the Year at the NSW Premiers Awards for Outstanding Cancer Research, and receiving the Royal College of Pathologists of Australasia (RCPA) Distinguished Fellow Award 2020The University of Sydney’s 2020 Alumni Award for International Achievement and being named the Clarivate Web of Science Group “Highly Cited Researcher 2020”. 

Despite his global research and clinical leadership, Professor Scolyer remains firm in his belief that the huge advances in melanoma treatment are a true team effort.

‘We have an amazing team of people doing world leading melanoma research and it’s a huge honour to be leading that team and to be recognised in this way,’ Professor Scolyer said.

‘Every cancer patient ultimately has their cancer diagnosed by a pathologist; what we see down the microscope and our research breakthroughs determine how a patient is treated and managed. Our research provides opportunity not only to benefit a single patient, but to make a difference to many thousands of patients for years to come, and that is what continues to drive us all.’

MIA CEO Matthew Brown commented: "The recognition of Richard completes an extraordinary quartet of honours awarded to the current and most recent medical directorship of MIA. A/Prof Jon Stretch AM (2012), Prof John Thompson AO (2014), Prof Georgina Long AO (2020) and now Prof Richard Scolyer AO (2021). MIA is truly fortunate that its mission has been and continues to be steered by such eminent Australians."

Australia has the highest melanoma rates in the world, with one person diagnosed with the disease every 30 minutes. 1300 Australians are expected to die from the disease this year. Melanoma is also the most common cancer impacting 15 to 39-year-olds.

 

Watch Prof Scolyer speaking about this achievement on #9News:

 

For more information, please contact:

Jennifer Durante - Melanoma Institute Australia - Ph 0412 798 990 Email: jennifer.durante@melanoma.org.au

Next Steps for National Screening Program for Melanoma
23 Mar 2020

Next Steps for National Screening Program for Melanoma

On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.

Melanoma March Update
13 Mar 2020

Melanoma March Update

Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.   

Saving lives this summer: 'Game On Mole!'
11 Mar 2020

Saving lives this summer: 'Game On Mole!'

Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.

PBS boost for melanoma patients
01 Mar 2020

PBS boost for melanoma patients

Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.

An open letter to all young Australians
25 Feb 2020

An open letter to all young Australians

Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.

MIA leads world-class skin tumour pathology conference
14 Feb 2020

MIA leads world-class skin tumour pathology conference

Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.

MAFS, it is time for a reality check on solariums.
07 Feb 2020

MAFS, it is time for a reality check on solariums.

It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.

Community Fundraising January Wrap-Up
07 Feb 2020

Community Fundraising January Wrap-Up

Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.

Kyly Clarke urges Aussies to step up to save lives from melanoma
03 Feb 2020

Kyly Clarke urges Aussies to step up to save lives from melanoma

Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.

Improving support for our patients across Australia.
03 Feb 2020

Improving support for our patients across Australia.

Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.   

Boost to melanoma support in WA
31 Jan 2020

Boost to melanoma support in WA

Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.

New Test to Predict Primary Melanoma Progression
21 Jan 2020

New Test to Predict Primary Melanoma Progression

Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.

Community Fundraising December Wrap-Up
14 Jan 2020

Community Fundraising December Wrap-Up

We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.

Two melanoma treatments approved for PBS listing
24 Dec 2019

Two melanoma treatments approved for PBS listing

Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.    

Immunotherapy: the decade's biggest health advance
23 Dec 2019

Immunotherapy: the decade's biggest health advance

An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.  

 

Boost to Melanoma Services in the Riverina
12 Dec 2019

Boost to Melanoma Services in the Riverina

Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.

Winner of the SunSafe Student Ambassador Program announced
11 Dec 2019

Winner of the SunSafe Student Ambassador Program announced

Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.

Community Fundraising November Wrap-Up
04 Dec 2019

Community Fundraising November Wrap-Up

It’s time again to say thank you to our amazing community fundraisers!

MIA & MPA Patient Information Evening videos now available
03 Dec 2019

MIA & MPA Patient Information Evening videos now available

Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.

MIA shines in poster session
22 Nov 2019

MIA shines in poster session

MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.